Anti-Tumor Necrosis Factor Drugs, Enthesitis, Spondyloarthritis
Conditions
Brief summary
Biological therapies should be considered in patients with high disease activity despite nonsteroid antiinflammatory drug treatment. The first option among biological therapies is anti-Tumor Necrosis Factor (anti-TNF) drugs. In recent years, anti-TNF treatments have shown that clinical and ultrasonographic enthesitis may improve as well as disease activity, quality of life and acute phase reactants. In this prospective study, we aimed to evaluate the clinical and ultrasonographic evaluation of enthesitis and to determine its response to anti-TNF treatment in patients with SpA.In this prospective study, we aimed to evaluate the clinical and ultrasonographic evaluation of enthesitis and to determine its response to anti-TNF treatment in patients with SpA.
Interventions
DRUGTNF Inhibitor
TNF inhibitors are widely used in patients with spondyloarthritis
Sponsors
Gunay ER
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE
Masking description
All patients were evaluated by the researcher who had a 10-year experience of musculoskeletal ultrasonography and is blind to clinical evaluation.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Spondyloarthritis patients were diagnosed according to 2009 Assessment of Spondyloarthritis International Society (ASAS) criteria
Exclusion criteria
* Severe cardiovascular and respiratory diseases, * Severe liver and kidney failure, * Pregnancy and lactation, * Active infection, * Malignancy, * Demyelinating diseases, * Systemic lupus erythematosus, * History of knee, elbow, foot and ankle surgery, * Fluoroquinolone, retinoid and fluoride use, * Local corticosteroid injection at the examination sites within the six weeks before evaluation * Peripheral neuropathy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| change from ultrasonographic entesitis score at 3 months | before and 3 months after anti-TNF treatment | Madrid Sonographic Enthesitis Index was used to screen etheseal sites |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from disease activity | before and 3 months after anti-TNF treatment | Bath Ankylosing Spondylitis Disease Activity Index was used |
| Change from quality of life | before and 3 months after anti-TNF treatment | Ankylosing Spondylitis Quality of Life was used |
| Change from Functionality | before and 3 months after anti-TNF treatment | Bath Ankylosing Spondylitis Functionality Index was used |
Outcome results
None listed